Beijing Biocytogen (China)
百奥赛图（股票代码：02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地。基于底层基因编辑技术，百奥赛图自主研发了RenMice®（RenMab®、RenLite®、RenNano®、RenTCR mimicTM）平台，用于全人治疗性单克隆抗体、双/多特异性抗体、双抗ADC、纳米抗体和类TCR抗体的发现。百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发（“千鼠万抗TM”计划），并已建立起超100万条全人抗体序列库，用于全球合作。
Basic Information
- Category: business
- Founded: 2021
- Website: http://www.bbctg.com.cn/
Documented Facts
- Email: info@biocytogen.com.cn (No linked source recorded for this statement.)
Evidence and Sources
- Beijing Biocytogen (China) — Official Site (official)
- Beijing Biocytogen (China) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Beijing Biocytogen (China).
- Canonical profile: https://brandsource.ai/brands/beijing-biocytogen-china
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/beijing-biocytogen-china/json-ld
- Citation profile API: https://brandsource.ai/api/brands/beijing-biocytogen-china/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Structured profile (63/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Beijing Biocytogen (China) is listed in business on BrandSource.AI.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
Known data gaps
- Needs a specific, non-thin summary
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.